Purpose: Huntington’s Disease (HD) is a fully penetrant neurodegenerative disease leading to cognitive and motor disturbances. The retina may serve as a structural and functional extension of the central nervous system to identify biomarkers of HD using noninvasive imaging technology such as optical coherence tomography angiography (OCTA) and dark adaptometry.

Methods: This case–control study included 12 HD participants (24 eyes) recruited from the Huntington’s Disease Society of America Center of Excellence at Washington University in St. Louis along with 16 control participants (31 eyes). Disease-positive participants underwent imaging testing of retinal capillary density and foveal avascular zone utilizing OCTA along with dark adaptometry testing. Data were collected from November 2020 to February 2022.

Results: Individuals with HD had a lower mean age-adjusted superficial foveal capillary density and a higher mean deep foveal capillary density compared to control subjects. There was no significant difference in the mean foveal avascular zone or in dark adaptometry testing between the two groups.

Conclusion: This study suggests that changes in retinal biomarkers may exist in patients with HD and that additional investigations using multimodal techniques are warranted.

2. Patton N, Aslam T, Macgillivray T, Pattie A, Deary IJ, Dhillon B. Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: A rationale based on homology between cerebral and retinal microvasculatures. J Anat 2005;206:319–348.

3. Gariano RF, Gardner TW. Retinal angiogenesis in development and disease. Nature 2005;438:960–966.

4. Shah A, Apte RS. Optical coherence tomography angiography: A window into central nervous system neurodegeneration. Trends Mol Med 2020;26:892– 895.

5. O’Bryhim BE, Lin JB, Van Stavern GP, Apte RS. OCT angiography findings in preclinical Alzheimer’s disease: 3-year follow-up. Ophthalmology 2021;128:1489–1491.

6. O’Bryhim BE, Apte RS, Kung N, Coble D, Van Stavern GP. Association of preclinical Alzheimer disease with optical coherence tomographic angiography findings. JAMA Ophthalmol 2018;136:1242–1248.

7. Ma JP, Robbins CB, Lee JM, Soundararajan S, Stinnett SS, Agrawal R, et al. Longitudinal analysis of the retina and choroid in cognitively normal individuals at higher genetic risk of Alzheimer disease. Ophthalmol Retina 2022;6:607–619.

8. Lee CS, Apte RS. Retinal biomarkers of Alzheimer disease. Am J Ophthalmol 2020;218:337–341.

9. Tsokolas G, Tsaousis KT, Diakonis VF, Matsou A, Tyradellis S. Optical coherence tomography angiography in neurodegenerative diseases: A review. Eye Brain 2020;12:73–87.

10. Makita S, Hong Y, Yamanari M, Yatagai T, Yasuno Y. Optical coherence angiography. Opt Express 2006;14:7821–7840.

11. Koustenis A Jr, Harris A, Gross J, Januleviciene I, Shah A, Siesky B. Optical coherence tomography angiography: An overview of the technology and an assessment of applications for clinical research. Br J Ophthalmol 2017;101:16–20.

12. Spaide RF, Fujimoto JG, Waheed NK, Sadda SR, Staurenghi G. Optical coherence tomography angiography. Prog Retin Eye Res 2018;64:1–55.

13. Flamendorf J, Agrón E, Wong WT, Thompson D, Wiley HE, Doss EL, et al. Impairments in dark adaptation are associated with age-related macular degeneration severity and reticular pseudodrusen. Ophthalmology 2015;122:2053–2062.

14. McColgan P, Tabrizi SJ. Huntington’s disease: A clinical review. Eur J Neurol 2018;25:24–34.

15. Kersten HM, Danesh-Meyer HV, Kilfoyle DH, Roxburgh RH. Optical coherence tomography findings in Huntington’s disease: A potential biomarker of disease progression. J Neurol 2015;262:2457–2465.

16. Gulmez Sevim D, Unlu M, Gultekin M, Karaca C. Retinal single-layer analysis with optical coherence tomography shows inner retinal layer thinning in Huntington’s disease as a potential biomarker. Int Ophthalmol 2019;39:611– 621.

17. Amini E, Moghaddasi M, Habibi SAH, Azad Z, Miri S, Nilforushan N, et al. Huntington’s disease and neurovascular structure of retina. Neurol Sci 2022;43:5933–5941.

18. Di Maio LG, Montorio D, Peluso S, Dolce P, Salvatore E, De Michele G, et al. Optical coherence tomography angiography findings in Huntington’s disease. Neurol Sci 2021;42:995–1001.

19. Wei Y, Jiang H, Shi Y, Qu D, Gregori G, Zheng F, et al. Age-related alterations in the retinal microvasculature, microcirculation, and microstructure. Invest Ophthalmol Vis Sci 2017;58:3804–3817.

20. Lin C-Y, Hsu Y-H, Lin M-H, Yang T-H, Chen H-M, Chen YC, et al. Neurovascular abnormalities in humans and mice with Huntington’s disease. Exp Neurol 2013;250:20–30.

21. Drouin-Ouellet J, Sawiak SJ, Cisbani G, Lagacé M, Kuan W-L, Saint-Pierre M, et al. Cerebrovascular and blood-brain barrier impairments in Huntington’s disease: Potential implications for its pathophysiology. Ann Neurol 2015;78:160–177.

22. Paulus W, Schwarz G, Werner A, Lange H, Bayer A, Hofschuster M, et al. Impairment of retinal increment thresholds in Huntington’s disease. Ann Neurol 1993;34:574–578.

23. Pearl JR, Heath LM, Bergey DE, Kelly JP, Smith C, Laurino MY, et al. Enhanced retinal responses in Huntington’s disease patients. J Huntingtons Dis 2017;6:237–247.

24. Knapp J, VanNasdale DA, Ramsey K, Racine J. Retinal dysfunction in a presymptomatic patient with Huntington’s disease. Doc Ophthalmol 2018;136:213– 221.